DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Ramalingam SS, Blackhall F, Krzakowski M et al.
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
J Clin Oncol 2012;
30: 3337-3344
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.